Fig. 6
From: The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Effect of Empagliflozin on vascularization after stroke. Confocal images (A) showing the expression in the striatum of non-diabetic controls (non-T2D), diabetic mice (T2D-VH) and diabetic mice treated with Empagliflozin (T2D-E) after stroke of CD13 (red) and PDXL (blue) evaluating vessel density (B), pericyte density (C), pericyte coverage (D) and parenchymal pericyte density (E). White arrows indicate the pericytes that are not associated with the vessels. Data are presented as mean ± SD. Statistical significance was calculated using two-way ANOVA followed by Benjamini, Krieger and Yekutieli multiple comparisons test. Results were considered statistically significant if p < 0.05. *denotes a difference between non-T2D and T2D-VH, §denotes a difference between T2D-VH and T2D-E, #denotes a difference between contralateral and ipsilateral hemisphere within the same group. Scale bar = 50 μm. non-T2D n = 5, T2D-VH n = 5, T2D-E n = 6